Vaccination with myelin oligodendrocyte glycoprotein adsorbed to alum effectively protects DBA/1 mice from experimental autoimmune encephalomyelitis

European Journal of Immunology

Volumn 33, Issue 6, 2003, Pages 1539-1547

  Wållberg, Maja ^a   Wefer, Judit ^a   Harris, Robert A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alum; EAE; MOG; Mouse; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CELL PROLIFERATION; CELL SELECTION; CELL SPECIFICITY; CONTROLLED STUDY; EXPERIMENTAL DESIGN; FEMALE; IMMUNIZATION; IMMUNOADSORBENT; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; INTERFERON PRODUCTION; METHODOLOGY; MOUSE; MOUSE STRAIN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADSORPTION; ALUM COMPOUNDS; ANIMALS; ANTIGENS, CD4; AUTOANTIGENS; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; RATS; RECOMBINANT PROTEINS; SPINAL CORD; TH2 CELLS; VACCINATION;

EID: 0038082369     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200323772     Document Type: Review

References (44)

1. Burns, J., Rosenzweig, A., Zweiman, B. and Lisak, R. P., Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell. Immunol. 1983. 81: 435-440.
2. Arnold, B., Schonrich, G. and Hammerling, G. J., Multiple levels of peripheral tolerance. Immunol. Today 1993. 14: 12-14.
3. Harrison, L. C. and Hafler, D. A., Antigen-specific therapy for autoimmune disease. Curr Opin. Immunol. 2000. 12: 704-711.
4. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. and Toda, M., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995. 155: 1151-1164.
5. Jiang, H., Braunstein, N. S., Yu, B., Winchester, R. and Chess, L., CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc. Natl. Acad. Sci. U S A 2001. 98: 6301-6306.
6. Singh, A. K., Wilson, M. T., Hong, S., Olivares-Villagomez, D., Du, C., Stanic, A. K., Joyce, S., Sriram, S., Koezuka, Y. and Van Kaer, L., Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 2001. 194: 1801-1811.
7. Heeger, P. S., Forsthuber, T., Shive, C., Biekert, E., Genain, C., Hofstetter, H. H., Karulin, A. and Lehmann, P. V., Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J. Immunol. 2000. 164: 5771-5781.
8. Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. and Weiner, H. L., Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994. 265: 1237-1240.
9. Meyer, A. L., Benson, J. M., Gienapp, I. E., Cox, K. L. and Whitacre, C. C., Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein, J. Immunol. 1996. 157: 4230-4238.
10. Waisman, A., Ruiz, P. J., Hirschberg, D. L., Gelman, A., Oksenberg, J. R., Brocke, S., Mor, F., Cohen, I. R. and Steinman, L., Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. 1996. 2: 899-905.
11. Lobell, A., Weissert, R., Storch, M. K., Svanholm, C., de Graaf, K. L., Lassmann, H., Andersson, R., Olsson, T. and Wigzell, H., Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 1998. 187: 1543-1548.
12. Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S. and Gupta, C. K., Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993. 11: 293-306.
13. Yip, H. C., Karulin, A. Y., Tary-Lehmann, M., Hesse, M. D., Radeke, H., Heeger, P. S., Trezza, R. P., Heinzel, F. P., Forsthuber, T. and Lehmann, P. V., Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 1999. 162: 3942-3949.
14. Del Giudice, G., Podda, A. and Rappuoli, R., What are the limits of adjuvanticity? Vaccine 2001. 20: S38-S41.
15. Mattsson, L., Lorentzen, J. C., Svelander, L., Bucht, A., Nyman, U., Klareskog, L. and Larsson, P., Immunization with alum-collagen II complex suppresses the development of collagen-induced arthritis in rats by deviating the immune response. Scand. J. Immunol. 1997. 46: 619-624.
16. Yang, X. and Hayglass, K. T., Allergen-dependent induction of interleukin-4 synthesis in vivo. Immunology 1993. 78: 74-79.
17. Olsson, T., Zhi, W. W., Hojeberg, B., Kostulas, V., Jiang, Y. P., Anderson, G., Ekre, H. P. and Link, H., Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 1990. 86: 981-985.
18. Feldmann, M., Brennan, F. M. and Maini, R. N., Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996. 14: 397-440.
19. Ramiya, V. K., Shang, X. Z., Pharis, P. G., Wasserfall, C. H., Stabler, T. V., Muir, A. B., Schatz, D. A. and Maclaren, N. K., Antigen based therapies to prevent diabetes in NOD mice. J. Autoimmun. 1996. 9: 349-356.
20. McFarland, H. I., Lobito, A. A., Johnson, M. M., Nyswaner, J. T., Frank, J. A., Palardy, G. R., Tresser, N., Genain, C. P., Mueller, J. P., Matis, L. A. and Lenardo, M. J., Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol. 1999. 162: 2384-2390.
21. Abdul-Majid, K. B., Jirholt, J., Stadelmann, C., Stefferl, A., Kjellen, P., Wallstrom, E., Holmdahl, R., Lassmann, H., Olsson, T. and Harris, R. A., Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J. Neuroimmunol. 2000. 111: 23-33.
22. Abdul-Majid, K. B., Stefferl, A., Bourquin, C., Lassmann, H., Linington, C., Olsson, T., Kleinau, S. and Harris, R. A., Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 2002. 55: 70-81.
23. Svensson, L., Abdul-Majid, K. B., Bauer, J., Lassmann, H., Harris, R. A. and Holmdahl, R., A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur. J. Immunol. 2002. 32: 1939-1946.
24. Rinella, J. V., White, J. L. and Hem, S. L., Effect of pH on the elution of model antigens from aluminum-containing adjuvants. J. Colloid Interface Sci. 1998. 205: 161-165.
25. Bach, J. F., Immunosuppressive therapy of autoimmune diseases. Immunol. Today 1993. 14: 322-326.
26. Wardrop, R. M. 3rd and Whitacre, C. C., Oral tolerance in the treatment of inflammatory autommune diseases. Inflamm. Res. 1999. 48: 106-119.
27. IFNB Multiple Sclerosis Study Group, U. M. M. A. G., Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996. 47: 889-894.
28. Aharoni, R., Meshorer, A., Sela, M. and Arnon, R., Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J. Neuroimmunol. 2002. 126: 58-68.
29. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. and Kuchroo, V. K., An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995. 3: 397-405.
30. Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., McFarland, H. F. and Martin, R., Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000. 6: 1167-1175.
31. Genain, C. P., Cannella, B., Hauser, S. L. and Raine, C. S., Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999. 5: 170-175.
32. Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F. M., Gessner, J. E., Schiller, C., Schmidt, R. E., Honjo, T., Verbeek, J. S. and Izui, S., Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fc gamma receptor III. J. Exp. Med. 2000. 191: 1293-1302.
33. Issazadeh, S., Lorentzen, J. C., Mustafa, M. I., Hojeberg, B., Mussener, A. and Olsson, T., Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. J. Neuroimmunol. 1996. 69: 103-115.
34. Young, D. A., Lowe, L. D., Booth, S. S., Whitters, M. J., Nicholson, L., Kuchroo, V. K. and Collins, M., IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 2000. 164: 3563-3572.
35. Segal, B. M., Dwyer, B. K. and Shevach, E. M., An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autommune disease. J. Exp. Med. 1998. 187: 537-546.
36. Hong, S., Wilson, M. T., Serizawa, I., Wu, L., Singh, N., Naidenko, O. V., Miura, T., Haba, T., Scherer, D. C., Wei, J., Kronenberg, M., Koezuka, Y. and Van Kaer, L., The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001. 7: 1052-1056.
37. Genain, C. P., Abel, K., Belmar, N., Villinger, F., Rosenberg, D. P., Linington, C., Raine, C. S. and Hauser, S. L., Late complications of immune deviation therapy in a nonhuman primate. Science 1996. 274: 2054-2057.
38. Lenz, D. C., Wolf, N. A. and Swanborg, R. H., Strain variation in autoimmunity: attempted tolerization of DA rats results in the induction of experimental autoimmune encephalomyelitis. J. Immunol. 1999. 163: 1763-1768.
39. Lafaille, J. J., Keere, F. V., Hsu, A. L., Baron, J. L., Haas, W., Raine, C. S. and Tonegawa, S., Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 1997. 186: 307-312.
40. Tuohy, V. K., Yu, M., Yin, L., Kawczak, J. A., Johnson, J. M., Mathisen, P. M., Weinstock-Guttman, B. and Kinkel, R. P., The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 1998. 164: 93-100.
41. Vanderlugt, C. L., Neville, K. L., Nikcevich, K. M., Eagar, T. N., Bluestone, J. A. and Miller, S. D., Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 2000. 164: 670-678.
42. Kenney, J. S., Hughes, B. W., Masada, M. R and Allison, A. C., Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Methods 1989. 121: 157-166.
43. Amor, S., Groome, N., Linington, C., Morris, M. M., Dornmair, K., Gardinier, M. V., Matthieu, J. M. and Baker, D., Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J. Immunol. 1994. 153: 4349-4356.
44. Muhallab, S., Lidman, O., Weissert, R., Olsson, T. and Svenningsson, A., Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2001. 113: 202-211.